Report: Antivirals TOC

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
HIV Antivirals
NRTIs
NNRTIs
Protease Inhibitor (PI)
Other HIV Antivirals
Hepatitis B & C Antivirals
Hepatitis B Antivirals
Hepatitis C Antivirals
Herpes Simplex Virus (HSV) Antivirals
Influenza Antivirals
Respiratory Syncytial Virus (RSV) Antivirals
Human Papilloma Virus (HPV) Antivirals
Other Antivirals

II. EXECUTIVE SUMMARY

1. Market Overview

Viruses, a Difficult - to - Treat Class of Parasites
United States - The Largest Market for Antivirals Globally
Five Major Antivirals Dominate the Overall Antivirals Arena
Table 1: Worldwide Infectious Disease Drugs Market by Class: 2005 Percentage Share Breakdown by Typefor Antivirals, Quinolones, Macrolides, Penicillins, Cephalosporins, Antifungals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart)
Anti-HIV Drugs - The Largest Antivirals Category Worldwide
US - Largest Region, and Japan - Fastest Growing Region for HIV Antivirals
Table 2: World HIV Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
Table 3: World HIV Antivirals Market by Geographic Region - Percentage Share Breakdown for US, Japan, Europe, and Rest of World (excluding Japan) for the Year 2006 (includes corresponding Graph/Chart)
Leading Players and Drugs
Top 10 HIV Antiviral Drug Candidates by Global Sales
New Drugs in Pipeline to Boost up the HIV
Antivirals Sales
Hepatitis Antivirals - A Significant Market
US Dominates the Hepatitis B & C Antivirals Market
Table 4: World Hepatitis B & C Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
Hepatitis C Antivirals - The Fastest Growing Antivirals Segment
U S Dominates the Hepatitis C Antivirals Market
Table 5: World Hepatitis C Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
The US Dominates the Hepatitis B Antivirals Market
Table 6: World Hepatitis B Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
Growing Patient Population to Drive up Hepatitis B Drugs Market
Influenza Anti-Virals
Rising Threat of Avian Flu to Drive up the Market for Antivirals
Herpes and Respiratory Antivirals
HSV/VZV Drugs Dominate the Herpes and Respiratory Antivirals Market
Launch of New Drugs to Drive up the Market for Respiratory Antivirals

2. Competitive Landscape

Players Active in the HIV Antivirals Market
Table 7: Leading Drug Brands for HIV Infection in the World: 2005 Sales (in $ million) for Combivir, Kaletra, Viread, Reyataz, Sustiva, Trizivir, Epivir, and Epzicom/Kivexa (includes corresponding Graph/Chart)
Major HIV Antivirals Brands Available in the Market
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Brands
Epivir (Lamivudine)
Retrovir (Zidovudine)
Combivir (Epivir+Retrovir)
Videx (Didanosine)
Zerit (Stavudine)
Hivid (Zalcitabine)
Protease Inhibitors (PIs)
Norvir (Ritonavir)
Kaletra (Lopinavir+Ritonavir)
Agenerase (Amprenavir)
(VX-175) Fosamprenavir
VX-385
Fusion Inhibitors
Fuzeon (Enfuvirtide)
Players Active in the Hepatitis B Virus (HBV) Drugs Market
Hepsera Leads the Oral Hepatitis B Antivirals Market
Table 8: Leading Drug Brands for Oral Hepatitis B Antivirals: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart)
Table 9: Leading Antivirals Brands for Hepatitis B Infection in the World: 2005 Sales (in $million) for *Engerix-B, Havrix, and Twinrix; **Infanrix and Pediarix, and Epivir (includes corresponding Graph/Chart)
Players in the Hepatitis C Virus (HCV) Drugs Market
Table 10: Leading Drug Brands for Oral Hepatitis B Antivirals in the World: 2005 Sales (in $million) for Pegasys and PEG-Intron
Table 11: Leading Players in the Pegylated Interferons Market in the World: 2006 Percentage Share Breakdown by Player for Hoffmann-La Roche, Schering-Plough and Others (includes corresponding Graph/Chart)
Table 12: Leading Therapies for Hepatitis C Infection in the World: 2006, 2010E and 2015E Percentage Share Breakdown for Ribavirin, Interferons, Protease Inhibitors, and Nucleoside Analogs (includes corresponding Graph/Chart)
Players in the Herpes and Respiratory Antiviral Market
Table 13: Leading Brands of the Respiratory Antivirals Market in the World: 2005 Sales (in $million) for Tamiflu; Synagis; Infanrix and Pediarix (includes corresponding Graph/Chart)
Players in the Herpes Simplex Virus (HSV) Therapies Market
Table 14: Leading Drug Brands for Oral Herpes Antivirals in the World: 2004 Sales (in $million) for Valtrex and Zovirax
Major HSV Infection Drugs Available
Zovirax (Aciclovir)
Famvir (Famciclovir)
Foscavir (Foscarnet)
Valtrex (Valaciclovir)
Vectavir/Denavir (Penciclovir)
Abreva (Docosanol)
Players in the Influenza Market
Major Influenza Drugs Available
Symmetrel® (Amantadine)
Flumadine (Rimantadine)
Tamiflu (Oseltamivir)
Relenza (Zanamivir)
Players in the Antivirals (Non-HIV) Market
Table 15: Global Leading Players in the Antivirals (Non-HIV) Market: 2005 Percentage Share Breakdown for GlaxoSmithKline (GSK), Novartis, Roche, Schering-Plough and Others (includes corresponding Graph/Chart)
Players Active in the Antiviral Vaccines Market
Table 16: Leading Antiviral Vaccines Sales (in US$ million) in US/Europe in 2003 (includes corresponding Graph/Chart)
Table 17: Leading Players in the US & **5EU Vaccines Markets: 2005 Percentage Share Breakdown by Player for GlaxoSmithKline (GSK), Sanofi-Aventis, Merck, *Novartis (Chiron) and Others (includes corresponding Graph/Chart)
Product Pipeline Development of Hepatitis C Drugs as of 2006

3. Market Trends & Issues

Increased Investment in R&D to Fuel Growth
Preventative Antivirals Gains Significance
New Drug Types Fuels Up the HIV Drugs Sector
Development of Direct Targeted Antiviral Therapies
Advent of Novel Anti-Viral Peptides
siRNA Shows Potential to Function as Antiviral Agent
Reduction of HIV/AIDS Therapy Costs Boost Market Growth
Combination Drug Therapy Gains Popularity in the Anti-HIV Drugs Market
Empowering Women to Fight Against Spread of HIV Infection
Prices to Go Up for Novel Antivirals
Competition Scales up for Nucleoside/Nucleotide Analogs Class of Hepatitis Antivirals
Emergence of Oligonucleotide (ODN) Agents in HIV Drugs Market
PMBs to Invade the Antivirals Market
Acute Shortage Witnessed for the Influenza Vaccine for the 2004-05 Season
New Therapies for Treatment Naive Hepatitis Patients
Adult and Travel Vaccines to Drive Up the Market for Antiviral Vaccines
Researches to Develop Antivirals for Other Miscellaneous Viral Diseases on Full Swing
Growth to Slow Down Considerably for Herpes Antiviral Market
STDs, a Major Concern the World Over
Microbiocides, a New Way to Fight STD and HIV Infections
Spread of HIV Infection Poses a Global Health Risk

4. An Overview of Major Viral Epidemics & Pandemics in the World

HIV/AIDS Pandemics
HIV/AIDS Cases for 2005 in the World
Highlights of AIDS Epidemic
Table 18: Global HIV/AIDS Statistics in 2005
(in Million) (includes corresponding Graph/Chart)
Table 19: Regional Statistics for HIV/AIDS Cases in 2005 (in Million) (includes corresponding Graph/Chart)
Table 20: Deaths Due to AIDS Worldwide: Breakdown by Region- 2004 (in Million) (includes corresponding Graph/Chart)
Table 21: HIV/AIDS Cases in Adults and Children Worldwide: Breakdown by Region-End 2004
Table 22: Countries With the Highest Number of People Living with HIV: 2003 (includes corresponding Graph/Chart)
Various Organizations Actively Supports HIV/AIDS Awareness and Preventive Measures Programs
Table 23: Regional Distribution of Requirement of Funding for Prevention of AIDS: Percentage Share Breakdown for Africa, East Asia-Pacific, South & South East Asia, Eastern Europe, Latin America & Caribbean Region, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart)
Table 24: Regional Distribution of Requirement of Funding for Treatment and Care of AIDS: Percentage Share Breakdown for Africa, Latin America & Caribbean Region, East Asia-Pacific, Eastern Europe, South & South East Asia, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart)
Hepatitis B Virus (HBV) Infection Epidemic
Hepatitis C Virus (HCV) Infection Epidemic
Table 25: Diagnosis of Hepatitis C Infection in the World: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Sexual Contact, Contaminated Blood Transfusion and Others (includes corresponding Graph/Chart)
Influenza - Major Outbreaks

5. Anti-Virals : Product Overview

What are Viruses?
RNA & DNA Viruses
Emergence of Antivirals
Functions of Antivirals
Design Strategies for Antivirals Drugs
Vaccines, the Antivirals for Initial Stage of Viral Infection
Antivirals for Other Stages of Viral Life Cycle
Entry Blockers
Viral Component Replication Blockers
Viral Component Assimilation Blockers
Antisense Molecules
Synthetic Ribozymes
Protease Inhibitors
Blockers for Release of Completed Viruses from the Host Cell
Other Types of Antivirals
Interferons
Synthetic Monoclonal Antibodies
Factors Governing Developments in Antiviral Technology

6. Major Viral Infections and Treatment Worldwide

Human Immunodeficiency Virus (HIV)
Transmission of HIV Infection
Infection Process - Targets for HIV Therapy
Symptoms of the Infection
Most Vulnerable Demographics for HIV Infection
Preventive Methods for Controlling HIV Infection
Methods for the Measurement of Viral Load in Patients
Methods for Determining Drug Resistance in HIV Positive Patients
Major HIV/AIDS Testing Methods Available
Diagnostic Tests
I. Antibody Tests
A. HIV-1 Screening Tests
a. Enzyme-linked Immunosorbent Assays/Enzyme Immunoassays (ELISA/EIA)
b. Home AccessHIV-1 test system/Dried Blood Spot
c. Rapid Tests...
B. HIV-1 Antibody Confirmatory Tests
a. The Western Blot Test
b. Indirect Immunofluorescent Antibody Assay (IFA)
c. Line Immunoassay
d. Radioimmunoprecipitation Assay (RIPA)
C. HIV-2 Diagnostic Tests and HIV Group "O
Major Trends in the HIV/AIDS Testing Market
Rapid Testing- Displays High Potential
FDA Approved Rapid HIV Tests in US
Molecular Diagnostics Register Strong Growth in Blood Screening Markets
Ultra-Rapid HIV-screening tests- A Strong Fight against HIV-Epidemic
Emergency Room Testing to Help HIV Diagnosis
Treatments Available for HIV/AIDS Infections
Major HIV/AIDS Drug Categories Available
NRTIs
NNRTIs
GW695634
Protease Inhibitor (PI)
(VX-175) Fosamprenavir
VX-385
Integrase Inhibitors (IIs)
S-1360
Entry Blockers
Fusion Inhibitors
Fuzeon (Enfuvirtide)
Antiviral siRNAs
New Products in Pipeline
HIV Vaccines
Hepatitis Infection
Acute Hepatitis Infection
Chronic Hepatitis Infection
Treatment Regimens for Hepatitis Infection
Interferons
Standard Interferons
Pegylated Interferons
Pegasys
N & PEG-Intron Redipen
Pegasys Pack
N & Pegatron
Ribavirin
Types of Hepatitis Infection based on Strains
Hepatitis A Virus (HAV) Infection
Hipatitis B Virus
Hepatitis B Virus (HBV) Infection
Treatments Available for Chronic HBV Infection
Vaccines Dominates the Category
Antiviral Drugs Available
Hepatitis C Virus (HCV) Infection
Treatments Available for Chronic Hepatitis C Infection
Products in Pipeline
Some Alternative Treatments
Hepatitis D Virus (HDV) Infection
Hepatitis E Virus (HEV) Infection
Herpes Simplex Virus (HSV) Infection
HSV-1 Infection
HSV-2 Infection
Neonatal Herpes Simplex Infection
Treatments Available for HSV Infection
Table Containing Major HSV Drugs along with their Patent Expiry Dates
HSV Antivirals Available in the Market
Treatments for Opthalmic Viral Infections
Cytovene (Ganciclovir)
Vistide (Cidofovir)
Foscavir (Foscarnet)
Vaccines Against HSV Infection
Respiratory Viruses Infections
Influenza Virus
Influenza A Virus
Avian Flu
Influenza - Brief History
Transmission of Influenza Infection
Treatments for Respiratory Viruses
Influenza Vaccines
Respiratory Syncytial Virus (RSV) Infection
Other Respiratory Viruses
Treatments for RSV and other Respiratory Viral Infections
Human Papilloma Virus (HPV)
Treatments Available for HPV Infection
Other Types of Viral Diseases
Treatment Options Available for Other Types of Viral Diseases
Overview of Antiviral Vaccines

7. International Organizations Supporting Preventative and Treatment Programs for Viral Infections

UNHCR
UNICEF
WFP
UNDP
UNPF
UNODC
ILO
UNESCO
WHO
World Bank
National AIDS Trust

8. Product Developments and Launches

Bristol-Myers Unveils Baraclude in India
Chinese and US Researchers Together Develop Purified Antiviral Compounds
Celldex to Develop a Fusion Protein CDX 2401
PDSC Launches a Germicidal Disinfectant, Medic Kleen
REPLICor to Develop Antiviral Drugs
Valeant Pharmaceuticals to Develop Viramidine(R)
Biota Discovers a New Group of Antiviral Drugs against RSV
Serum Launches Q-Vac, a Combination Vaccine
Chongqing Jiachen to Produce Hepatitis B Vaccine
IIL Decides to Roll Out Five Vaccines in Indian Market
Shanta Biotechnics to Foray into US Markets with AlphaFeto and Shanvac B
GSK Launches Hepsera for Chronic Hepatitis B
Viral Therapeutics Takes Over Development Rights to Recombinant Human Protein
Biota Inc Introduces New AZT Nucleotide Mimic Drug for HIV/AIDS
SciGen Ltd Introduces Sci-B-Vac Vaccine for Hepatitis B in Hong Kong
Aurobindo Pharma Ltd Launches Indivex and Stavex Anti-HIV Drugs
Trimeris and Roche Collaboratively Develops Two Fusion Inhibitors

9. Recent Industry Activity

Adventrx Takes Over SD Pharmaceuticals
Nutra Pharma to Acquire ReceptoPharm
Dynavax Acquires German Rhein Biotech
Barrier Acquires Rights to Market Denavir from Norvartis
Chimerix Acquires Leroy Townsend Library of Lead Drug Candidates
Sareum Collaborates with Idenix to Develop Antivirals
CSIRO Collaborates with Bath University to Create an Oral Antiviral Agent
GlaxoSmithKline and Shionogi to Co-Develop HIV Drugs
Inovio Biomedical Corporation Enters into an Agreement with Tripep AB
Roche Partners with Trimeris to Develop HIV Fusion Inhibitor Drugs
Pfizer and Monogram Execute a Non-Exclusive Collaboration
Novartis Enters into an Agreement with Human Genome Sciences
Medivir Inks Licensing Deal with Tibotec for HBV and HIV Drugs
Boehringer to Enhance its Canadian Antiviral Research Center
GSK Receives Pediatric Extension of Hevrix Vaccine in the US
GSK Completes Phase II Clinical Trial on Promacta
Schering-Plough Undertakes Clinical Trials on Some Hepatitis Products
Gilead Sciences and Merck Conducts Clinical Trials (Phase I / II) on HIV Integrase Inhibitor
Vertex to Start Phase IIb Trials for VX-950
Schering-Plough Starts Phase II Trials for SCH 503034
Panacos Pharmaceuticals Initiates Phase 2b Studies on Bevirimat
Immune Response Corporation Initiates IR103 Phase II Trial
Health Enhancement Products Inc to Conduct ProAlgaZyme Clinical Trial
Novartis Secures FDA Approval for Famvir
Novelos Therapeutics, Inc Gains FDA Acceptance of INDA for NOV-205
Gilead Sciences and Bristol-Myers-Squibb Obtains FDA License for Atripla
Tibotec Obtains FDA Approval for Darunavir
Amazon Receives Consent for Phase I/II Trials for AMZ0026
MedImmune Applies for Supplemental License for CAIV-T
FermaVir Pharmaceuticals Obtains FDA Approval for Further Studies on Antiviral Drug Candidate
Abbott Obtains FDA Assent for ABBOTT PRISM® and PRISM® Blood Screening
Abbott Receives Authorization from European Commission to Market Kaletra®
Schering-Plough Receives Marketing Approval for PEG-INTRON® and REBETOL® Drugs
Idenix and Novartis Submit Drug Application to European Regulators for Telbivudine
Merck Obtains FDA Approval for Marketing GARDASIL® Vaccine
Merck' s GARDASIL Vaccine Gets CHMP' s Positive Opinion
Boehringer Ingelheim Demonstrates the Clinical Trial Results of Aptivus® Capsules
GlaxoSmithKline Demonstrates Results for H5N1 Pandemic Flu Vaccine Clinical Trials
GlaxoSmithKline Minimizes Prices of HIV Drugs in Poor Countries
Donations Rises for AIDS Orphanage in South Africa
FDA to Ban the Usage of Human Antiviral Drugs for Influenza Treatment in Poultry
Third Wave Withdraws Lawsuit against Digene Relating to Patent on HPV Drug
Roche Files Suit against Ranbaxy to Restrain Launch of Antiviral Generic Drug
Dainippon Pharmaceutical to Merge with Sumitomo Pharmaceuticals
Abbott and OraSure Enter into Agreement
Hemispherx Biopharma Signs a Research Agreement with Defence R&D Canada
LUPIN and Cornerstone Sign Licensing Agreement to Develop Anti-Infective Product
Trimeris Inc Enters into Collaborative Agreement with ChemBridge Research Laboratories
Corixa Corporation Collaborates with Lorantis
Takeda Enters into HPV Collaborative Agreement with 3M
MedImmune Inks Collaborative Licensing Agreement with Biota
Pharmasset Enters into License Agreement with Bukwang Pharm
Chiron and Enanta Pharmaceuticals Enter into HCV PI Development Agreement
Gilead Sciences Enters into JTK-303 License Agreement with Japan Tobacco
Alnylam and Isis Enter into Licensing Deal with Stanford University
Gen-Probe and F. Hoffmann-La Roche Enter into an Agreement
SciGen Limited Enters into Hepatitis B Vaccine Distribution Agreement with Berna Biotech AG
GSK Receives Supply Order for Relenza from Governments of Three Countries
Bristol-Myers to Establish Production Facility in China
Koronis Initiates Phase 1b Trial for KP-1461 Antiviral
Gilead Initiates Phase III Clinical Trials for Tenofovir
Vaccine Research Center Initiates Phase II Trials onAdenovector
Aethlon Medical Instigates Clinical Trials of HCV
Hemispherx Biopharma Initiates Alferon LDO Clinical Trials
Bristol-Myers and Merck Provide IPM with License to Develop HIV Vaccines
Hi-Tech' s Acyclovir Oral Suspension Secures FDA Approval
Bristol-Myers Squibb Gains FDA Approval for the company' s Entecavir
Corixa' s Fendrix® Vaccine Receives European Approval
Calypte Biomedical' s HIV-1 Urine EIA Screening Test Receives FDA Approval
Gilead Sciences' s Truvada® Receives Marketing Authorization
Abbott Receives FDA Approval to Formulate Kaletra in Tablet Form
Boehringer Ingelheim Receives EU Approval to Market Aptivus
Boehringer Ingelheim Secures FDA Approval to Market Aptivus
SciClone Releases Poster Presentation of Zadaxin® Triple Therapy
GlaxoSmithKline Discloses Clinical Findings for Brecanavir
Abbott and Celera Secure CE Mark Certification for PCR Test
Gilead Sciences Cuts Prices for Truvada and Viread for Developing Nations
Gilead Sued Roche for not Properly Marketing Tamiflu and Receives Damage Payment
MGI PHARMA to Purchase Zycos
Benitec Ltd Acquires Avocel Inc
ID Biomedical Takes Over Vaccine Business of Shire
SGX Forms Alliance with Roche to Develop New Antivirals
Epimmune and Innogenetics Extend Collaboration Agreement
Nucleonics and Novosom Collaborate to Develop New Antivirals
Gilead Sciences and Achillion Pharmaceuticals Sign Licensing Agreement
ZymoGenetics Licenses Drug Development Rights to Novo Nordisk
Cubist and XTL Sign Development Agreement
Sunesis and Merck Signs Research Agreement
CytoGenix Files Pre-IND Brief with the FDA
ViroPharma Signs Licensing Agreement with Schering-Plough
Hemispherx Inks Agreement with GMC for Development and Commercialization of HIV Antivirals
DNA-C and NYVAC Combination AIDS Vaccine To Enter Clinical Trial Stage
GlaxoSmithKline Plc Reduces Anti-AIDS Treatment Prices in Poor Countries
Gilead Acquires Triangle Pharmaceuticals
Micrologix Acquires Antivirals Portfolio of Origenix
Roche Acquires HPV Patent Portfolio from Pasteur Institute
Johnson & Johnson Enters into an Agreement to Acquire Tibotec-Virco NV
USL Signs Licensing Agreement with Novactyl
Micrologix Biotech and Hybridon Signs Collaborative Licensing Agreement
Novartis Acquires a Portfolio of Antivirals from SmithKline Beecham
Biota Inc' s Bird Flu Drug Relenza Receives FDA Approval

10. Focus on Select Key Players

Abbott Laboratories (USA)
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb (USA)
Gilead Sciences (USA)
GlaxoSmithKline Plc. (UK)
Hoffmann-La Roche (Switzerland)
Merck & Co. (USA)
Novartis AG (Switzerland)
Pfizer Inc. (USA)
Schering-Plough Corp. (USA)

11. Global Market Perspective

Table 26: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 27: World Recent Past, Current & Future Analysis for Antivirals by Product Segment - HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals Independently Analyzed by Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 28: World 10-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 29: World 10-Year Perspective for Antivirals by Product Segment - Percentage Breakdown of Dollar Sales for HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 30: World Recent Past, Current & Future Analysis for HIV Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 31: World 10-Year Perspective for HIV Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 32: World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 33: World 10-Year Perspective for Hepatitis B & C Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 34: World Recent Past, Current & Future Analysis for Hepatitis C Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 35: World 10-Year Perspective for Hepatitis C Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 36: World Recent Past, Current & Future Analysis for Hepatitis B Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 37: World 10-Year Perspective for Hepatitis B Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A. Market Analysis
Infectious Disease Drugs Market in the US
Table 38: Infectious Disease Drugs Market by Class in the US: 2005 Percentage Share Breakdown by Type for Quinolones, Penicillins, Macrolides, Antifungals, Cephalosporins, Antivirals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart)
Antivirals Market Perspective in the US
HIV Antivirals Dominate the Antiviral Therapies Market in the US, followed by the Hepatitis B & C Antivirals Class
Table 39: Antivirals Market by Type in the US: 2006 Percentage Share Breakdown for HIVAntivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart)
Combivir Dominates the Reverse Transcriptase Inhibitors Market in the US
Table 40: Reverse Transcriptase Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Combivir, Zerit, Epivir, Sustiva, Viramune, Ziagen, Videx, Retrovir and *Others (includes corresponding Graph/Chart)
Table 41: Leading Players in the HIV Reverse Transcriptase Inhibitors (RTIs) Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Bristol-Myers Squibb and *Others (includes corresponding Graph/Chart)
Viracept Dominates the Protease Inhibitors Market in the US
Table 42: Protease Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Viracept, Crixivan, Norvir, Fortovase, Agenerase and Invirase (includes corresponding Graph/Chart)
Table 43: Leading Players in the HIV Protease Inhibitors (PIs) Market in the US: 2005 Percentage Share Breakdown for Abbott Laboratories, Pfizer and *Others (includes corresponding Graph/Chart)
Hepatitis B Infection Prevalence in the US
Hepsera Dominates the Oral Hepatitis B Antivirals Market
Table 44: Leading Brands in the Oral Hepatitis B Antivirals Market in the US: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart)
New Emerging Therapies for HBV Infection in the US
Emerging Hepatitis B Infection Antivirals in Phase II Clinical Trials in the US
Emerging Hepatitis B Infection Antivirals in Phase I Clinical Trials in the US
Hepatitis C Antivirals Market in the US
Table 45: Leading Players in the Hepatitis C Antivirals Market in the US: 2005 Percentage Share Breakdown for Schering Plough and *Others
Table 46: Leading Brands in the Interferon Hepatitis C Antivirals Market in the US: 2006 Percentage Share Breakdown for Pegasys, PEG Intron, Copegus and Rebetol (includes corresponding Graph/Chart)
HSV Antivirals in the US
Table 47: Leading Players in the HSV Antivirals Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Generics and *Others (includes corresponding Graph/Chart)
Influenza Antivirals Market in the US
Emerging Influenza Antivirals in the Clinical Development Stage in the US
TIV Dominates the US Influenza Vaccines Market
Table 48: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Type for Treated (Killed) Influenza Vaccine (TIV) and Live Attenuated Influenza Vaccine (LAIV)
Fluzone Rules the Roost in the Influenza Vaccines Market
Table 49: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Brand for Fluzone, Fluvirin, Fluarix and FluMist (includes corresponding Graph/Chart)
Table 50: Leading Players in the Influenza Antivirals Market in the US: 2005 Percentage Share Breakdown for Roche and *Others
HIV/AIDS Prevalence in the US
Homosexual Males Emerges as a Significant Risk Group for HIV Infections in the US
Table 51: Diagnosis of HIV/AIDS among Adult and Adolescent Males in the US: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug User (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart)
Table 52: Ethnic Group Distribution of HIV/AIDS Cases Among Men with Homosexual Contacts in the US: 2005 Percentage Share Breakdown for Whites, African Americans, Latin Americans, Asian/Pacific Islander and American Indian/Alaska Native (includes corresponding Graph/Chart)
Women, a High Risk Group for HIV/AIDS in the US
Table 53: AIDS Cases Reported in the US Among Females 13 and Older: 2005 Percentage Share Breakdown by Ethnic Community for African American Women, Latin American Women, White Women and Others (includes corresponding Graph/Chart)
Table 54: Diagnosis of HIV/AIDS among Adult and Adolescent Females in the US: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug User (IDU) and Others (includes corresponding Graph/Chart)
African Americans, the Leading High Risk Ethnic Group for HIV Infection in the US
Table 55: Individuals Living with AIDS in the US: 2005 Percentage Share Breakdown by Ethnic Community for African Americans, Whites, Latin Americans and Others (includes corresponding Graph/Chart)
Latinos, the Second Major Ethnic Risk Group for HIV Infection in the US
Zidovudine (ZDV) Emerges as a Major Drug to Prevent Mother-to-Child Transmission of HIV Infection
An Overview of Sexually Transmitted Diseases (STDs) in the US
Regulatory Environment for HIV/AIDS in the US
Product Launches
Strategic Corporate Developments
Focus on Key Players
3M
Abbott Laboratories
Amazon Biotech
Bristol-Myers Squibb
FermaVir Pharmaceuticals
Gilead Sciences
Hemispherx Biopharma
MedImmune Inc.
Merck & Co.
Novartis Pharmaceuticals
Novelos Therapeutics
Panacos Pharmaceuticals
Pfizer Inc.
Pharmasset
Schering-Plough Corporation
B. Market Analytics
Table 56: US Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 57: US Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment - RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 58: US 10-Year Perspective for HIV Antivirals by Product Segment - Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 59: US Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 60: US 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis BAntivirals for the Years 2000, 2006 & 2010

2. Japan

A. Market Analysis
Japanese Antivirals Market Perspective
HIV Infection Prevalence in Japan
Hepatitis B & C Antivirals Dominate the Japanese Antivirals Market
Japan, the Second Largest Market for Hepatitis C Infection in the World
Table 61: Leading Drug Brands for Hepatitis C Antivirals in Japan: 2005, 2006 and 2008E Percentage Share Breakdown for PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon, Feron and Others (includes corresponding Graph/Chart)
Product Launch
Strategic Corporate Developments
Focus on Key Players
Daiichi Pharmaceutical Co.
Japan Tobacco
B. Market Analytics
Table 62: Japanese Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 63: Japanese Recent Past, Current & Future Analysis for HIV Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 64: Japanese Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 65: Japanese 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010

3. Europe

A. Market Analysis
France - The Largest and the Fastest Growing Market for Antivirals
HIV Therapy Dominates the Antivirals Market
Table 66: Antivirals Market by Type in Europe: 2006 Percentage Share Breakdown for HIV Antivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart)
HIV/AIDS Prevalence in Europe
HIV/AIDS Statistics in Western Europe
UK Dominates the Market for Western Europe for HIV Infection
Table 67: Diagnosis of HIV Infection among Adults in Western Europe: 2005 Percentage Share Breakdown by Region for UK, Portugal, **France, Germany, The Netherlands, *Italy, Belgium, Switzerland and Others (includes corresponding Graph/Chart)
HIV/AIDS Statistics in Central Europe
Poland Dominates the Market for Central Europe for HIV Infection
Table 68: Diagnosis of HIV Infection among Adults in Central Europe: 2005 Percentage Share Breakdown by Region for Poland, Romania, Turkey, Serbia & Montenegro, Czech Republic, Hungary, Bulgaria and Others (includes corresponding Graph/Chart)
HIV/AIDS Statistics in Eastern Europe
Russia Dominates the Market for Eastern Europe for HIV Infection
Table 69: Diagnosis of HIV Infection among Adults in Eastern Europe: 2005 Percentage Share Breakdown by Region for Russia, *Ukraine, Uzbekistan, Belarus, Estonia, Kazakhstan, Republic of Moldova, Latvia and Others (includes corresponding Graph/Chart)
Herpes Antivirals
Strategic Corporate Developments
B. Market Analytics
Table 70: European Recent Past, Current & Future Analysis for Antivirals by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 71: European 10-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain and Rest of Europe for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 72: European Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment - RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 73: European 10-Year Perspective for HIV Antivirals by Product Segment -Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 74: European Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 75: European 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment- Percentage Breakdown of Value Sales for Hepatitic C Antivirals and Hepatitis B Antivirals for Years 2000, 2006 & 2010

3a. France

A. Market Analysis
France the Largest and Fastest Growing Antivirals Market in Europe
Strategic Corporate Developments
B. Market Analytics
Table 76: French Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3b. Germany

A. Market Analysis
Germany the Second Largest and Fastest Growing Antivirals Market in Europe
Strategic Corporate Developments
Focus on Key Player
Boehringer Ingelheim
B. Market Analytics
Table 77: German Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3c. Italy

A. Market Analysis
Strategic Corporate Developments
B. Market Analytics
Table 78: Italian Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3d. The United Kingdom

Market Analysis
UK the Third Largest Market for Antivirals in Europe
HIV/AIDS Prevalence in the UK
Table 79: Diagnosis of HIV Infection among Individuals in the UK: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Black- Africans, Black-Caribbeans and Others (includes corresponding Graph/Chart)
Table 80: Diagnosis of AIDS among Adult Males in the UK: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart)
Table 81: Diagnosis of AIDS among Adult Females in the UK: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Mother-to-Child Transfer, Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart)
Table 82: Diagnosis of HIV Infection in People in the UK: 2005 Percentage Share Breakdown by Region for England, Scotland, Wales and North Ireland (includes corresponding Graph/Chart)
Drug Resistant HIV Strains Rising in the UK
Rise in Sexually Transmitted Diseases Pose Health Risks
Strategic Corporate Developments
Focus on Key Player
GlaxoSmithKline PLC
B. Market Analytics
Table 83: UK Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3e. Spain

A. Market Analysis
B. Market Analytics
Table 84: Spanish Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
3f. Rest of Europe
A. Market Analysis
Russia
Acute Supply Shortage of AIDS drugs Risks the Life of Many People in Russia
Strategic Corporate Developments
Focus on Key Players
Hoffmann-La Roche (Switzerland)
Novartis AG (Switzerland)
B. Market Analytics
Table 85: Rest of Europe Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

4. Rest of World

A. Market Analysis
Canada
HIV/AIDS Prevalence in Canada
Table 86: Diagnosis of HIV Infection among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU, Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart)
Table 87: Diagnosis of HIV Infection among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart)
Table 88: Diagnosis of AIDS among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart)
Table 89: Diagnosis of AIDS among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU) and Others (includes corresponding Graph/Chart)
Table 90: Individuals Living with AIDS in Canada: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Aboriginals, Blacks, South Asian/West Asian/Arab, Asians and Others (includes corresponding Graph/Chart)
Hepatitis C Infection Prevalence in Canada
Asia-Pacific
HIV/AIDS Prevalence in Asia
HIV Infection Among Males Rising
Australia
HIV/AIDS Prevalence in Australia
Table 91: Diagnosis of HIV Infections in Australia: 2005 Percentage Share Breakdown by Region for New South Wales, Victoria, Queensland, Western Australia, South Australia, Australian Capital Territory and Others (includes corresponding Graph/Chart)
Hepatitis C Infection Prevalence in Australia
Table 92: Sources of Hepatitis C Infection Transmission in Australia: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Blood Transfusion/Medical, Tattoos/Piercing, Sexual Contact and Others (includes corresponding Graph/Chart)
Bangladesh
HIV/AIDS Prevalence in Bangladesh
Cambodia
HIV/AIDS Prevalence in Cambodia
China
Antivirals Market in China
China Presents a Major Market for Hepatitis B Therapies
HIV/AIDS Prevalence in China
Hong Kong
HIV/AIDS Prevalence in Hong Kong
India
Hepatitis B Vaccines Market in India
Table 93: Hepatitis B Vaccine Market in India: 2005 Percentage Share Breakdown by Player for Shantha Biotech, Glaxo SmithKline and Others (includes corresponding Graph/Chart)
HIV/AIDS Prevalence in India
Table 94: AIDS Cases Diagnosed in India: 2005 Percentage Share Breakdown by Gender for Males and Females
Table 95: Diagnosis of HIV/AIDS Cases in India: 2005 Percentage Share Breakdown by Transmission Category for Sexual Contact, Mother-to-Child Transfer, Injecting Drug Use (IDU), Blood and Blood Products, and Others (includes corresponding Graph/Chart)
Table 96: Diagnosis of AIDS Cases in India: 2005 Percentage Share Breakdown by Geographic Region for Tamil Nadu, Maharashtra, Andhra Pradesh, Karnataka, Manipur, West Bengal, Kerala, Madhya Pradesh, Uttar Pradesh, Rajasthan and Others (includes corresponding Graph/Chart)
India Emerging as a Major Market for HIV-Infected People in the World
Table 97: Diagnosis of HIV Infection in India: 2005 Percentage Share Breakdown by Sub-Population for General Population, STD Patients, Injecting Drug Users (IDUs), Children and Female Sex Workers (FSWs) (includes corresponding Graph/Chart)
Organizations Active in Executing HIV/AIDS Control and Prevention Programs
Table 98: Institutional Funding for HIV/AIDS Control Programs in India: 2005 Percentage Share Breakdown by Funding Organization for Public Bodies, Bilateral Organizations, World Bank, Multilateral Organizations and Global Funds (includes corresponding Graph/Chart)
India Steps Up Infrastructure Development to Control
and Prevent the Spread of Viral Infections
New Treatment Options to Fight Against HIV Infection
AIDS Control Programs for Rural Youths in India
Indonesia
HIV/AIDS Prevalence in Indonesia
Myanmar (Burma)
HIV/AIDS Prevalence in Myanmar
Nepal
HIV/AIDS Prevalence in Nepal
New Zealand
HIV/AIDS Prevalence in New Zealand
Pakistan
HIV/AIDS Prevalence in Pakistan
Singapore
HIV/AIDS Prevalence in Singapore
South Korea
HIV/AIDS Prevalence in South Korea
Thailand
HIV/AIDS Prevalence in Thailand
Viet Nam
HIV/AIDS Prevalence in Viet Nam
Hepatitis B Infection Prevalence in Viet Nam
Latin America
HIV/AIDS Prevalence in Latin America
Table 99: Diagnosis of People Living with HIV/AIDS in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Mexico, Colombia, Argentina, Venezuela, Peru, Honduras, Guatemala, El Salvador, Ecuador, Panama, Paraguay and Others (includes corresponding Graph/Chart)
Table 100: Diagnosis of AIDS Related Deaths in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Colombia, Mexico, Venezuela, Peru, Argentina, Honduras, Guatemala, El Salvador, Ecuador, Panama and Others (includes corresponding Graph/Chart)
HIV/AIDS Prevalence in the Caribbean Region
Table 101: Diagnosis of People Living with HIV/AIDS in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica, Bahamas, Cuba and Barbados (includes corresponding Graph/Chart)
Table 102: Diagnosis of AIDS Related Deaths in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica and Others (includes corresponding Graph/Chart)
Africa
HIV/AIDS Prevalence in Sub-Saharan Africa
Table 103: Diagnosis of People Living with HIV/AIDS in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Mozambique, Zimbabwe, United Republic of Tanzania, Kenya, Ethiopia, Zambia, Democratic Republic of Congo, Uganda and Others (includes corresponding Graph/Chart)
Table 104: Diagnosis of AIDS Related Deaths in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Zimbabwe, Mozambique, United Republic Of Tanzania, Kenya, Ethiopia, Zambia, Uganda, Malawi and Others (includes corresponding Graph/Chart)
Table 105: Diagnosis of AIDS Related Orphans in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Kenya, United Republic Of Tanzania, Zimbabwe, Uganda, Nigeria, Ethiopia, Zambia, Democratic Republic of Congo, Malawi and Others (includes corresponding Graph/Chart)
South Africa
Television Exposures Induces Healthy Lifestyle Changes Among People to Combat HIV/AIDS Epidemic
HIV/AIDS Prevalence in South Africa
Middle East
HIV/AIDS Prevalence in Middle East
Product Launches
Strategic Corporate Developments
Focus on Select Players
Bukwang Pharm (South Korea)
Benitec Limited (Australia)
B. Market Analytics
Table 106: Rest of World Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 107: Rest of World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
Table 108: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
Table 109: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010

IV. COMPETITION

1. 3M Company (USA)
Table 110: First Quarter Sales Analysis: 2005-2006 (In US$ billion)
Table 111: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion)
Table 112: Annual Sales Analysis: 2004-2005 (In US$ billion)
Table 113: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
Table 114: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
3M Pharmaceuticals (USA)
2. Abbott Laboratories (USA)
Table 115: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 116: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 117: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
Table 118: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 119: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 120: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
Table 121: Annual sales Analysis by Geographic Region: 2004-2005 (In US$ million)
3. Achillion Pharmaceuticals, Inc. (USA)
4. Adithya Pharmaceuticals Pvt., Ltd. (India)
5. Adventrx Pharmaceuticals, Inc. (USA)
6. Aeterna Zentaris, Inc. (Canada)
Table 122: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 123: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 124: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
Table 125: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
7. Aethlon Medical, Inc. (USA)
8. Alfacell Corporation (USA)
9. Alnylam Pharmaceuticals, Inc. (USA)
Table 126: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 127: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
10. Amarillo Biosciences (USA)
Table 129: Half Yearly Sales Analysis 2005-2006 (H1) (US$ Million)
Table 130: Annual Sales Analysis 2004-2005 (US$ Million)
11. Amazon Biotech (USA)
12. Amgen, Inc. (USA)
Table 131: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 132: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 133: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
13. Anadys Pharmaceuticals (USA)
Table 134: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 135: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 136: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
14. Antigenics, Inc. (USA)
Table 137: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 138: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 139: Annual Sales Analysis: 2004-2005 (In US$ million)
15. Ares Serono (France)
16. Array BioPharma, Inc. (USA)
Table 140: Annual Sales Analysis: 2004-2005 (In US$ million)
17. Arrow Pharmaceuticals (Australia)
18. Aspen Pharmacare Holding Ltd. (South Africa)
Table 141: Annual Sales Analysis: 2004-2005 (In R million)
19. Astral Pharmaceuticals (India)
20. Astellas Pharma, Inc. (Japan)
21. AstraZeneca PLC (UK)
Table 142: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 143: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million)
Table 144: Annual Sales Analysis: 2003-2005 (In US$ million)
Table 145: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
22. Aurobindo Pharma Ltd. (India)
Table 146: Annual Sales Analysis: 2004-2005 (In INR million)
23. Avanir Pharmaceuticals (USA)
Table 147: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, June) (In US$ million)
Table 148: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, June) (In US$ million)
Table 149: Nine Months Sales Analysis by Segment: 2005-2006 (Nine Months ended, June) (In US$ million)
Table 150: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 151: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 152: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
24. Bavarian Nordic A/S (Denmark)
Table 153: Half Yearly Sales Analysis: 2006-2005 (H1) (In DKK million)
Table 154: Annual Sales Analysis: 2004-2005 (In DKK million)
25. Bayer HealthCare AG (Germany)
Table 155: Annual Sales Analysis: 2004-2005 (In € million)
Table 156: Annual Sales Analysis by Segment: 2004-2005 (In € million)
Table 157: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
26. Becton Dickinson and Company (USA)
Table 158: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 159: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 160: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
Table 161: Annual Sales Analysis: 2004-2005 (In US$ million)
27. Benitec Ltd. (Australia)
28. Biomerieux SA (France)
29. Biomira, Inc. (Canada)
30. Biota Holdings Limited (Australia)
Table 162: Annual Sales Analysis: 2005-2006 (In US$ million)
31. Biovail Pharmaceuticals (Canada)
32. Boehringer Ingelheim GmbH (Germany)
Roxane Laboratories, Inc. (USA)
33. Bristol-Myers Squibb Company (USA)
Table 163: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
Table 164: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ billion)
Table 165: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion)
Table 166: Annual Sales Analysis: 2004-2005 (In US$ billion)
Table 167: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)
Table 168: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
Table 169: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
34. Bukwang Pharmaceutical Company Limited (South Korea)
35. Cavidi Tech AB (Sweden)
36. Celldex Therapeutics, Inc. (USA)
37. CEL-SCI Corporation (USA)
Table 170: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, June) (In US$ thousand)
Table 171: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, June) (In US$ thousand)
Table 172: Annual Sales Analysis: 2004-2005 (In US$ thousand)
38. ChemBridge Research Laboratories, Inc. (USA)
39. Chimerix, Inc. (USA)
40. Chongqing Jiachen Product Manufacturing Co., Ltd. (China)
41. Coley Pharmaceutical Group, Inc. (USA)
Table 173: Half-Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousand)
Table 174: Annual Sales Analysis: 2004-2005 (In Can$ thousand)
Table 175: Annual Sales Analysis by Quarter: 2005-2004 (In Can$ thousands)
42. Cornerstone BioPharma, Inc. (USA)
43. Cubist Pharmaceuticals, Inc. (USA)
Table 176: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 177: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 178: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
Table 179: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 180: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
44. Cytogenix, Inc. (USA)
45. Daiichi Pharmaceutical Co., Ltd. (Japan)
Table 181: Annual Sales Analysis: 2004-2005 (In ¥ billion)
Table 182: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion)
46. Dainippon Sumitomo Pharma Company Ltd. (Japan)
Table 183: Annual Sales Analysis: 2005-2006 (In ¥ million)
47. Digene Corporation (USA)
Table 184: Annual Sales Analysis: 2003-2005 (In US$ million)
Table 185: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
48. E. I. Du Pont De Nemours and Company (USA)
Table 186: Annual Sales Analysis: 2004-2005 (In US$ billion)
Table 187: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)
Table 188: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
Table 189: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
49. Eli Lilly and Company (USA)
Table 190: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)
Table 191: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million)
Table 192: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In US$ million)
Lilly Research Labs (USA)
50. Enanta Pharmaceuticals, Inc. (USA)
51. Endo Labs (USA)
52. Enzo Diagnostics, Inc. (USA)
53. F. Hoffmann-La Roche Ltd. (Switzerland)
Table 193: First Quarter Sales Analysis: 2005-2006 (In CHF billion)
Table 194: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion)
Table 195: Annual Sales Analysis: 2004-2005 (In CHF billion)
Roche Laboratories, Inc. (USA)
54. FermaVir Pharmaceuticals, Inc. (USA)
55. Flamel Technologies SA (France)
Table 196: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 197: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 198: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 199: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
56. Forest Laboratories, Inc. (USA)
Table 200: First Quarter Sales Analysis: 2006-2007 (In US$ billion)
Table 201: Annual Sales Analysis: 2004-2006 (In US$ billion)
Table 202: Annual Sales Analysis by Quarter: 2005-2006 (In US$ billion)
Table 203: Annual Sales Analysis by Product: 2005-2006 (In US$ billion)
Table 204: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ billion)
57. Galapagos NV (Belgium)
58. Genentech, Inc. (USA)
Table 205: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 206: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 207: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
59. Gen-Probe, Inc. (USA)
Table 208: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 209: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 210: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
60. Gilead Sciences, Inc. (USA)
Table 211: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In USS$ million)
Table 212: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million)
Table 213: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 214: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
61. Girindus AG (Germany)
62. GlaxoSmithKline PLC (UK)
Table 215: Annual Sales Analysis: 2003-2005 (In £ million)
Table 216: Annual Sales Analysis by Segment: 2004-2005 (In £ million)
Table 217: Annual Sales Analysis by Segment: 2003-2004 (In £ million)
63. Health Enhancement Products, Inc. (USA)
64. Hemispherx Biopharma, Inc. (USA)
Table 218: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand)
65. Hetero Drugs Ltd. (India)
66. Human Genome Sciences, Inc. (USA)
Table 219: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)
Table 220: Annual Sales Analysis: 2003-2005 (In US$ million)
67. Idenix Pharmaceuticals, Inc. (USA)
Table 221: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 222: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 223: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
68. Idera Pharmaceuticals, Inc. (USA)
69. Indian Immunologicals Ltd. (India)
70. Innogenetics NV (Belgium)
Table 224: Half Yearly Sales Analysis: 2004-2005 (H1) (In € million)
Table 225: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In € million)
71. Inovio Biomedical Corporation (USA)
Table 226: Half Yearly Sales Analysis by: 2005-2006 (H1) (In US$ million)
Table 227: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 228: Annual Sales Analysis: 2003-2005 (In US$ million)
Table 229: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
72. Intarcia Therapeutics Inc. (USA)
73. Intercell AG (Austria)
Table 230: Half Yearly Sales Analysis: 2005-2006 (H1) (In € thousand)
Table 231: Annual Sales Analysis: 2004-2005 (In € thousand)
74. InterMune, Inc. (USA)
Table 232: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 233: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
Table 234: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million)
Table 235: Annual Sales Analysis: 2003-2005 (In US$ million)
Table 236: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
Table 237: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
75. Isis Pharmaceuticals, Inc. (USA)
Table 238: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 239: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)
Table 240: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 241: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 242: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
76. Japan Tobacco, Inc. (Japan)
Table 243: Annual Sales Analysis: 2004-2006 (In ¥ billion)
Table 244: Annual Sales Analysis by Segment: 2005-2006 (In ¥ billion)
Table 245: Annual Sales Analysis by Geographic Region: 2005-2006 (In ¥ billion)
Table 246: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion)
Table 247: Annual Sales Analysis by Geographic Region: 2004-2005 (In ¥ billion)
77. Johnson & Johnson (USA)
Table 248: First Quarter Sales Analysis: 2005-2006 (In US$ billion)
Table 249: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion)
Table 250: First Quarter Sales Analysis by Geographic Region: 2005-2006 (Q1) (In US$ billion)
Janssen LP (USA)
Ortho-Clinical Diagnostics (USA)
Ortho Biotech Products - Tibotec Therapeutics Division (USA)
Tibotec Pharmaceuticals Ltd. (Ireland)
78. Koronis Pharmaceuticals, Inc. (USA)
79. Lupin Limited (India)
Table 251: First Quarter Sales Analysis: 2006-2007 (In INR billion)
Table 252: Annual Sales Analysis: 2004-2006 (In INR billion)
80. Medigene AG (Germany)
Table 253: Half Yearly Sales Analysis: 2005-2006 (H1) (In ¥ million)
Table 254: Half Yearly Sales Analysis by Quarter: 2005-2006 (In ¥ million)
Table 255: Annual Sales Analysis: 2004-2005 (In ¥ million)
81. Medimmune, Inc. (USA)
Table 256: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 257: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 258: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 259: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
82. Medivir AB (Sweden)
Table 260: Annual Sales Analysis: 2004-2005 (In SEK million)
83. Merck & Company, Inc. (USA)
Table 261: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 262: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 263: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million)
Table 264: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 265: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 266: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
Table 267: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
Merck Research Laboratories (USA)
84. MGI Pharma, Inc. (USA)
Table 268: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 269: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 270: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
85. Migenix, Inc. (Canada)
Table 271: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 272: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
86. Monogram Biosciences, Inc. (USA)
Table 273: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 274: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 275: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
87. Novactyl, Inc. (USA)
88. Novartis AG (Switzerland)
Table 276: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 277: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
Table 278: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 279: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
Table 280: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
Chiron Corporation (USA)
Novartis Pharmaceuticals Corporation (USA)
Sandoz International GmbH (Germany)
89. Novelos Therapeutics (USA)
Table 281: Annual Sales Analysis: 2004-2005 (In US$ million)
90. Novosom AG (Germany)
91. Nucleonics, Inc. (USA)
92. Oncogene Science, Inc. (USA)
93. OraSure Technologies, Inc. (USA)
Table 282: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 283: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 284: Half Yearly Sales Analysis by Segment: 2005-2006 (In US$ million)
Table 285: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million)
Table 286: Annual Sales Analysis: 2003-2005 (In US$ million)
Table 287: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 288: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
Table 289: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
94. Oxford BioMedica PLC (UK)
Table 290: Annual Sales Analysis: 2004-2005 (In £ million)
95. Panacos Pharmaceuticals, Inc. (USA)
96. Pasteur Merieux Connaught (France)
97. PDL BioPharma, Inc. (USA)
Table 291: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 292: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 293: Annual Sales Analysis: 2003-2005 (In US$ million)
98. Peregrine Pharmaceuticals, Inc. (USA)
Table 294: Annual Sales Analysis: 2004-2006 (In US$ million)
Table 295: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million)
Table 296: Annual Sales Analysis by Segment: 2005-2006 (In US$ million)
Table 297: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
99. Pfizer, Inc. (USA)
Table 298: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
Table 299: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion)
Table 300: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion)
Table 301: Annual Sales Analysis: 2004-2005 (In US$ billion)
100. Pharmasset, Inc. (USA)
101. Pharmexa A/S (Denmark)
Table 302: Half Yearly Sales Analysis: 2005-2006 (H1) (In DKK million)
102. Procter & Gamble Pharmaceuticals (USA)
103. Receptopharm, Inc. (USA)
104. REPLICor, Inc. (Canada)
105. Rhein Biotech NV (The Netherlands)
106. Sanofi-Aventis (France)
Table 303: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million)
Table 304: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million)
Table 305: Annual Sales Analysis: 2004-2005 (In € million)
Table 306: Annual Sales Analysis by Segment: 2004-2005 (In € million)
Table 307: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
107. Sareum Ltd. (UK)
108. Schering AG (Germany)
Table 308: First Quarter Sales Analysis: 2005-2006 (In € billion)
Table 309: First Quarter Sales Analysis by Segment: 2005-2006 (In € billion)
Table 310: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In € billion)
Table 311: Annual Sales Analysis: 2004-2005 (In € billion)
Table 312: Annual Sales Analysis by Segment: 2004-2005 (In € billion)
Table 313: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion)
Schering-Plough Corporation (USA)
109. SciClone Pharmaceuticals, Inc. (USA)
Table 314: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 315: Annual Sales Analysis: 2004-2005 (In US$ million)
110. Scigen Ltd. (Australia)
Table 316: Annual Sales Analysis: 2005-2006 (In S$ thousand)
Table 317: Annual Sales Analysis by Geographic Region: 2005-2006 (In S$ thousand)
111. Serum Institute of India Ltd. (India)
112. SGX Pharmaceuticals, Inc.(USA)
Table 318: First Quarterly Sales Analysis: 2005-2006 (In US$ million)
Table 319: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
Table 320: Annual Sales Analysis: 2004-2005 (In US$ million)
113. Shantha Biotechnics Pvt., Ltd. (India)
114. Shionogi & Co., Ltd. (Japan)
Table 321: Annual Sales Analysis: 2004-2005 (In ¥ million)
Table 322: Annual Sales Analysis by Segment: 2004-2005 (In ¥ million)
115. Sunesis Pharmaceuticals, Inc. (USA)
Table 323: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 324: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 325: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 326: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
116. Takeda Pharmaceutical Company Limited (Japan)
Table 327: Annual Sales Analysis: 2004-2006 (In ¥ billion)
117. Targeted Genetics Corporation (USA)
Table 328: Half Yearly Sales Analysis: 2005-2006 (In US$ million)
Table 329: Annual Sales Analysis: 2003-2005 (In US$ million)
118. TEVA Pharmaceutical Industries Ltd. (Israel)
Table 330: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ billion)
Table 331: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ billion)
Table 332: Half Yearly Geographic Sales Analysis: 2004-2005 (H1) (In US$ billion)
Ivax Corporation (USA)
119. The Immune Response Corporation (USA)
Table 333: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand)
Table 334: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ thousand)
Table 335: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ thousand)
Table 336: Annual Sales Analysis: 2003-2005 (In US$ thousand)
Table 337: Annual Sales Analysis by Quarter: 2004-2005 (In US$ thousand)
Table 338: Annual Sales Analysis by Segment: 2004-2005 (In US$ thousand)
120. Three Rivers Pharmaceuticals (USA)
121. Titan Pharmaceuticals, Inc. (USA)
122. Trimeris, Inc. (USA)
Table 339: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
123. Trinity Biotech PLC (Ireland)
Table 340: First Quarter Sales Analysis: 2005-2006 (In US$ million)
Table 341: First Quarter Sales Analysis by Product: 2005-2006 (In US$ million)
Table 342: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million)
Table 343: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 344: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
Table 345: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
124. Tripep AB (Sweden)
125. Valeant Pharmaceuticals International (USA)
Table 346: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 347: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 348: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 349: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
126. VaxGen, Inc. (USA)
127. Vertex Pharmaceuticals, Inc. (USA)
Table 350: First Quarter Sales Analysis: 2006-2005 (In US$ million)
Table 351: Annual Sales Analysis: 2003-2005 (In US$ million)
Table 352: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
128. Vical, Inc. (USA)
Table 353: Half Yearly Sales Analysis: 2005-2006 (In US$ million)
Table 354: Half Yearly Sales Analysis by Quarter: 2005-2006 (In US$ million)
Table 355: Annual Sales Analysis: 2004-2005 (In US$ million)
Table 356: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
129. Vion Pharmaceuticals (USA)
130. Viragen, Inc. (USA)
Table 357: Annual Sales Analysis: 2004-2006 (In US$ million)
Table 358: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ million)
Table 359: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
131. Virco Laboratories, Inc. (USA)
132. ViroPharma, Inc. (USA)
Table 360: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 361: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 362: Annual Sales Analysis: 2004-2005 (In US$ million)
133. Viscount Pharma, Inc. (Canada)
134. Vybion, Inc. (USA)
135. Wyeth (USA)
Table 363: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
Table 364: Half Yearly Sales Analysis by Segment: 2006-2005 (H1) (In US$ billion)
Table 365: Annual Sales Analysis: 2004-2005 (In US$ billion)
Table 366: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
Table 367: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
136. Xenomics, Inc. (USA)
137. XTL Biopharmaceuticals Ltd. (USA)
Table 368: Annual Sales Analysis: 2004-2005 (In US$ million)
138. ZymeTx, Inc. (USA)
139. ZymoGenetics, Inc. (USA)
Table 369: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
Table 370: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
Table 371: Annual Sales Analysis: 2004-2005 (In US$ million)

Antivirals

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Market Overview

2. Competitive Landscape

3. Market Trends & Issues

4. An Overview of Major Viral Epidemics & Pandemics in the World

5. Anti-Virals : Product Overview

6. Major Viral Infections and Treatment Worldwide

7. International Organizations Supporting Preventative and Treatment Programs for Viral Infections

8. Product Developments and Launches

9. Recent Industry Activity

10. Focus on Select Key Players

11. Global Market Perspective

III. MARKET

1. The United States

2. Japan

3. Europe

3a. France

3b. Germany

3c. Italy

3d. The United Kingdom

3e. Spain

4. Rest of World

IV. COMPETITION